Toripalimab Set For ASCO Buzz With New Nasopharyngeal Data
First-Line PFS Improvements
Junshi and Coherus's PD-1 was already gaining attention for a particularly difficult cancer type even before the meeting, but new data add to its luster ahead of a potential US approval.
You may also be interested in...
Keeping Track: Breakthroughs Of Summer Break Ground In Psychiatry, Cancer (Especially Nasopharygeal Cancer) And Vaccines
US FDA’s marquee expedited review program added 15 new breakthrough therapy designations between June and August.
In this week's podcast edition of Five Must-Know Things: Roche shores up oncology; Janssen’s multiple myeloma strategy; gene therapy safety; a new PD-1 inhibitor moves forward in the US; and herd immunity and COVID.
GSK could soon see an approval in Japan for its antibody therapy following a filing for emergency use, while South Korea looks to build its mRNA vaccine capabilities through a new consortium.